A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population,

(The Mount Sinai Hospital / Mount Sinai School of Medicine) The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol--the so-called "bad" cholesterol--by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.